Related Experiment Video
Updated: Jan 13, 2026
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
Clinical Utility of the aMAP Risk Score for Predicting the Recurrence of Hepatic Encephalopathy After Rifaximin
Satoshi Takakusagi1, Satoru Kakizaki2,3, Yozo Yokoyama1
1Department of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka, Japan.
Backgrounds:
This study aimed to investigate the incidence and potential risk factors for hepatic encephalopathy (HE) recurrence following the initiation of rifaximin therapy in patients with liver cirrhosis.
Methods:
We conducted a multicenter retrospective cohort study of cirrhotic patients who initiated rifaximin between December 2016 and December 2023. Patients with a prior episode of overt HE who received rifaximin for secondary prophylaxis were included. Clinical data, laboratory parameters, and concomitant medications were extracted from medical records. Factors associated with HE recurrence after rifaximin initiation were analyzed using univariate and multivariate analyses.
Results:
A total of 145 patients were included (median age, 70 years; male, 52.4%). During a median observation period of 26.4 months (interquartile range: 11.4-48.9), 52 patients (35.9%) experienced HE recurrence. In multivariate analysis, the baseline aMAP risk scores the only independent predictor of HE recurrence (p = 0.041). Receiver operating characteristic (ROC) analysis identified a cutoff value of 70.843 for the aMAP risk score to predict HE recurrence. Patients with an aMAP risk score below 70.843 had significantly lower cumulative recurrence rates than those with scores ≥ 70.843 (p = 0.012).
Conclusions:
Despite good tolerability, more than one-third of the patients experienced HE recurrence after rifaximin initiation. The aMAP risk score was useful for predicting the risk of recurrence, suggesting its potential clinical utility in the treatment of HE.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...